RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Agios Pharmaceuticals - Stock

Agios Pharmaceuticals Revenue 2024

Agios Pharmaceuticals Revenue

45.51 M USD

Ticker

AGIO

ISIN

US00847X1046

WKN

A1W2RM

In 2024, Agios Pharmaceuticals's sales reached 45.51 M USD, a 69.66% difference from the 26.82 M USD sales recorded in the previous year.

The Agios Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e1.012,36
2028e0.73,42
2027e0.445,40
2026e0.2310,35
2025e0.1317,92
2024e0.0552,61
20230.0389,26
20220.0188,06
2021--
2020--
2019--
20180.0998,52
20170.0455,67
20160.0734,26
20150.0640,50
20140.0736,63
20130.0393,71
20120.0395,35
20110.02109,62

Agios Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Agios Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Agios Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Agios Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Agios Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Agios Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Agios Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Agios Pharmaceuticals’s growth potential.

Agios Pharmaceuticals Revenue, Profit, and EBIT History

DateAgios Pharmaceuticals RevenueAgios Pharmaceuticals EBITAgios Pharmaceuticals Net Income
2029e1.01 B undefined0 undefined87.44 M undefined
2028e699.25 M undefined70.21 M undefined70.84 M undefined
2027e443.18 M undefined-110.18 M undefined-106.4 M undefined
2026e231.29 M undefined-335.25 M undefined-277.08 M undefined
2025e133.63 M undefined-381.35 M undefined-326.59 M undefined
2024e45.51 M undefined-378.17 M undefined-138.2 M undefined
202326.82 M undefined-391.49 M undefined-352.09 M undefined
202214.24 M undefined-389.04 M undefined-231.8 M undefined
20210 undefined-378.42 M undefined1.6 B undefined
20200 undefined-335.92 M undefined-327.37 M undefined
20190 undefined-316.27 M undefined-411.47 M undefined
201894.39 M undefined-362.48 M undefined-346.03 M undefined
201743.01 M undefined-320.79 M undefined-314.67 M undefined
201669.89 M undefined-200.99 M undefined-198.47 M undefined
201559.12 M undefined-118.7 M undefined-117.73 M undefined
201465.36 M undefined-54.13 M undefined-53.5 M undefined
201325.55 M undefined-38.88 M undefined-43.57 M undefined
201225.11 M undefined-23 M undefined-27.29 M undefined
201121.84 M undefined-16.63 M undefined-26.81 M undefined

Agios Pharmaceuticals stock margins

The Agios Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agios Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agios Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Agios Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Agios Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Agios Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Agios Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Agios Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Agios Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Agios Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Agios Pharmaceuticals Margin History

Agios Pharmaceuticals Gross marginAgios Pharmaceuticals Profit marginAgios Pharmaceuticals EBIT marginAgios Pharmaceuticals Profit margin
2029e89.26 %0 %8.63 %
2028e89.26 %10.04 %10.13 %
2027e89.26 %-24.86 %-24.01 %
2026e89.26 %-144.95 %-119.8 %
2025e89.26 %-285.38 %-244.4 %
2024e89.26 %-831 %-303.69 %
202389.26 %-1,459.52 %-1,312.63 %
202288.06 %-2,732.02 %-1,627.81 %
202189.26 %0 %0 %
202089.26 %0 %0 %
201989.26 %0 %0 %
201898.52 %-384.02 %-366.6 %
201789.26 %-745.85 %-731.62 %
201689.26 %-287.58 %-283.97 %
201589.26 %-200.78 %-199.14 %
201489.26 %-82.82 %-81.85 %
201389.26 %-152.17 %-170.53 %
201289.26 %-91.6 %-108.68 %
201189.26 %-76.14 %-122.76 %

Agios Pharmaceuticals Aktienanalyse

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals Inc. is a US biopharmaceutical company specializing in the development of treatment options for rare genetic disorders and cancer. The company was founded in 2008 by David Schenkein, Lewis Cantley, and Tak Mak and is headquartered in Cambridge, Massachusetts. The history of Agios Pharmaceuticals Inc. began with the discovery of IDH1 mutations, which are frequently found in many types of cancer. The founders of Agios recognized the significance of this discovery and laid the foundation for the development of drugs targeting this mutation. Agios' business model is to develop innovative therapeutics for diseases that are often neglected by other companies. The company focuses on researching enzymes that play important roles in genetic disorders and cancer processes. Agios collaborates closely with other companies and research institutions to quickly translate its research findings into clinical research and subsequent patient treatment. Additionally, the company has established itself as a pioneer in the application of artificial intelligence in drug development in recent years. Agios divides its portfolio into two main areas: oncology and rare genetic disorders. In oncology, the company utilizes targeted therapies based on a deep understanding of the underlying cancer biology. Therapeutic approaches include enzyme inhibitors, immunotherapies, and cell therapies. Agios has several promising candidates in clinical development in this area, including Idhifa for the treatment of acute myeloid leukemia, as well as Ivosidenib and Ag-120, both used to treat brain tumors. In the field of rare genetic disorders, Agios specializes in a group of enzyme defects known as citric acid cycle disorders. Agios is the only provider of drugs targeting these enzymes. The company recently received approval for Tibsovo for the treatment of acute myeloid leukemia in the United States. Agios aims to continuously expand its pipeline of therapeutics to meet the unmet need for treatments for rare diseases and cancer. The company has an extensive research pipeline, with several drugs in preclinical and clinical development. Agios works closely with other companies and research institutions to quickly translate its research findings into clinical development and subsequent patient treatment. Overall, Agios Pharmaceuticals has made impressive strides in recent years and has established itself as a key player in the biopharmaceutical industry. The company specializes in developing innovative therapies for rare genetic disorders and cancer and collaborates closely with other companies and research institutions. With its extensive research pipeline and the application of artificial intelligence, Agios is well-positioned to contribute to the development of new therapeutic options in the future. Agios Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Agios Pharmaceuticals's Sales Figures

The sales figures of Agios Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Agios Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Agios Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Agios Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Agios Pharmaceuticals Stock

How much revenue did Agios Pharmaceuticals generate this year?

Agios Pharmaceuticals has achieved a revenue of 45.51 M USD this year.

How much was the turnover of the company Agios Pharmaceuticals compared to the previous year?

The revenue of Agios Pharmaceuticals has increased by 69.66% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Agios Pharmaceuticals?

The revenue of Agios Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Agios Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Agios Pharmaceuticals so important for investors?

The revenue of Agios Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Agios Pharmaceuticals pay?

Over the past 12 months, Agios Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agios Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Agios Pharmaceuticals?

The current dividend yield of Agios Pharmaceuticals is .

When does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agios Pharmaceuticals?

Agios Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Agios Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agios Pharmaceuticals located?

Agios Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agios Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agios Pharmaceuticals from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Agios Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Agios Pharmaceuticals in the year 2023?

In the year 2023, Agios Pharmaceuticals distributed 0 USD as dividends.

In which currency does Agios Pharmaceuticals pay out the dividend?

The dividends of Agios Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Agios Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Agios Pharmaceuticals

Our stock analysis for Agios Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agios Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.